Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension

Goodall LJ, Ovecka M, Rycroft D, Friel SL, Sanderson A, Mistry P, Davies ML, Stoop AA. P. PLoS One. 2015 Sep 9;10(9):e0137065. PubMed PMID: 26352810; PubMed Central PMCID: PMC4564187.

Abstract: Tumour Necrosis Factor-α (TNF-α) inhibition has been transformational in the treatment of patients with inflammatory disease, e.g. rheumatoid arthritis. Intriguingly, TNF-α signals through two receptors, TNFR1 and TNFR2, which have been associated with detrimental inflammatory and beneficial immune-regulatory processes, respectively. To investigate if selective TNFR1 inhibition might provide benefits over pan TNF-α inhibition, tools to investigate the potential impact of pharmacological intervention are needed. Receptor-deficient mice have been very insightful, but are not reversible and could distort receptor cross-talk, while inhibitory anti-TNFR1 monoclonal antibodies have a propensity to induce receptor agonism...  Read the article here >

The murine PD study was performed by Biomedcode (Vari, Greece) under approved protocol numbers DOMEXP295/L44412. Mice were housed at Biomedcode's facilities under standardised light-controlled conditions at room temperature (20±2°C) and 55±15% humidity with free access to food and water.

 

 

Return to Publications